$625 Million is the total value of Affinity Asset Advisors, LLC's 59 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 80.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | New | SPDR S&P 500 ETF TRput | $338,730,000 | – | 750,000 | +100.0% | 54.19% | – |
| NARI | Buy | INARI MED INC | $19,941,000 | +74.8% | 220,000 | +76.0% | 3.19% | -23.0% |
| MORF | Buy | MORPHIC HLDG INC | $18,696,000 | -1.2% | 465,654 | +16.6% | 2.99% | -56.5% |
| KURA | Buy | KURA ONCOLOGY INC | $14,860,000 | +89.5% | 924,147 | +65.0% | 2.38% | -16.5% |
| ASND | New | ASCENDIS PHARMA A/Ssponsored adr | $14,083,000 | – | 120,000 | +100.0% | 2.25% | – |
| SWTX | Sell | SPRINGWORKS THERAPEUTICS INC | $13,941,000 | -24.7% | 247,000 | -17.3% | 2.23% | -66.8% |
| KDNY | Buy | CHINOOK THERAPEUTICS INC | $13,827,000 | +52.7% | 845,155 | +52.2% | 2.21% | -32.7% |
| ESTA | Buy | ESTABLISHMENT LABS HLDGS INC | $11,760,000 | +124.5% | 174,500 | +125.2% | 1.88% | -1.1% |
| Buy | TRAVERE THERAPEUTICS INCnote 2.500% 9/1 | $11,495,000 | +48.7% | 11,000,000 | +57.1% | 1.84% | -34.5% | |
| AZN | New | ASTRAZENECA PLCsponsored adr | $10,614,000 | – | 160,000 | +100.0% | 1.70% | – |
| ZNTL | Buy | ZENTALIS PHARMACEUTICALS INC | $9,574,000 | -3.1% | 207,500 | +76.6% | 1.53% | -57.3% |
| SWTX | New | SPRINGWORKS THERAPEUTICS INCput | $9,030,000 | – | 160,000 | +100.0% | 1.44% | – |
| New | NANOSTRING TECHNOLOGIES INCnote 2.625% 3/0 | $7,753,000 | – | 7,000,000 | +100.0% | 1.24% | – | |
| MDGL | Buy | MADRIGAL PHARMACEUTICALS INC | $7,359,000 | +33.6% | 75,000 | +15.4% | 1.18% | -41.2% |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $7,104,000 | -13.8% | 300,000 | +24.4% | 1.14% | -62.0% |
| ARYA SCIENCES ACQUISITN CORP | $6,828,000 | +0.3% | 702,500 | 0.0% | 1.09% | -55.8% | ||
| RPTX | Buy | REPARE THERAPEUTICS INC | $6,677,000 | +16.5% | 468,905 | +72.5% | 1.07% | -48.7% |
| PMVP | New | PMV PHARMACEUTICALS INCcall | $6,608,000 | – | 317,400 | +100.0% | 1.06% | – |
| LNTH | New | LANTHEUS HLDGS INC | $6,361,000 | – | 115,000 | +100.0% | 1.02% | – |
| NSTG | New | NANOSTRING TECHNOLOGIES INC | $5,963,000 | – | 171,592 | +100.0% | 0.95% | – |
| VINC | Buy | VINCERX PHARMA INC | $5,496,000 | -52.5% | 1,374,098 | +21.0% | 0.88% | -79.1% |
| PTGX | New | PROTAGONIST THERAPEUTICS INCput | $5,113,000 | – | 215,900 | +100.0% | 0.82% | – |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $4,758,000 | +32.1% | 300,000 | +81.8% | 0.76% | -41.8% |
| New | BRIDGEBIO PHARMA INCnote 2.250% 2/0 | $4,680,000 | – | 10,000,000 | +100.0% | 0.75% | – | |
| BRIDGEBIO PHARMA INCnote 2.500% 3/1 | $4,380,000 | -20.8% | 7,500,000 | 0.0% | 0.70% | -65.1% | ||
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $4,258,000 | +10.2% | 125,000 | +25.0% | 0.68% | -51.5% |
| BLU | Buy | BELLUS HEALTH INC NEW | $4,128,000 | +2.6% | 600,000 | +20.0% | 0.66% | -54.9% |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $3,957,000 | +4.3% | 1,272,244 | +13.4% | 0.63% | -54.0% |
| CRSP | New | CRISPR THERAPEUTICS AGcall | $3,452,000 | – | 55,000 | +100.0% | 0.55% | – |
| HZNP | New | HORIZON THERAPEUTICS PUB L | $3,156,000 | – | 30,000 | +100.0% | 0.50% | – |
| HSAQ | HEALTH SCIENCES ACQ CORP 2 | $2,973,000 | -0.9% | 300,000 | 0.0% | 0.48% | -56.3% | |
| MSAC | MEDICUS SCIENCES ACQUISITION | $2,934,000 | +0.6% | 300,000 | 0.0% | 0.47% | -55.7% | |
| TVTX | Buy | TRAVERE THERAPEUTICS INC | $2,577,000 | +66.0% | 100,000 | +100.0% | 0.41% | -27.0% |
| CERE | Sell | CEREVEL THERAPEUTICS HLDNG I | $2,451,000 | -66.4% | 70,000 | -68.9% | 0.39% | -85.2% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $2,446,000 | -48.0% | 80,000 | -46.8% | 0.39% | -77.1% |
| NAUT | Sell | NAUTILUS BIOTECHNOLOGY INC | $2,426,000 | -55.4% | 559,019 | -46.7% | 0.39% | -80.4% |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $2,425,000 | – | 70,000 | +100.0% | 0.39% | – |
| RLAY | New | RELAY THERAPEUTICS INCcall | $2,245,000 | – | 75,000 | +100.0% | 0.36% | – |
| LNTH | New | LANTHEUS HLDGS INCput | $2,212,000 | – | 40,000 | +100.0% | 0.35% | – |
| AUPH | New | AURINIA PHARMACEUTICALS INCcall | $2,167,000 | – | 175,000 | +100.0% | 0.35% | – |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $1,724,000 | -70.4% | 100,000 | -75.0% | 0.28% | -86.9% |
| BEAM | New | BEAM THERAPEUTICS INCcall | $1,719,000 | – | 30,000 | +100.0% | 0.28% | – |
| New | CONTEXT THERAPEUTICS INC | $1,687,000 | – | 777,610 | +100.0% | 0.27% | – | |
| CYCC | CYCLACEL PHARMACEUTICALS INC | $1,220,000 | -21.2% | 400,000 | 0.0% | 0.20% | -65.3% | |
| Buy | LIANBIOsponsored ads | $1,206,000 | +170.4% | 325,000 | +348.9% | 0.19% | +19.1% | |
| Buy | SCIENCE 37 HOLDINGS INC | $1,184,000 | -36.7% | 221,382 | +47.6% | 0.19% | -72.2% | |
| KRTX | New | KARUNA THERAPEUTICS INC | $951,000 | – | 7,500 | +100.0% | 0.15% | – |
| VRDN | New | VIRIDIAN THERAPEUTICS INC | $925,000 | – | 50,000 | +100.0% | 0.15% | – |
| ATHX | New | ATHERSYS INC NEWput | $858,000 | – | 1,416,400 | +100.0% | 0.14% | – |
| Buy | RENOVACOR INC | $846,000 | -12.1% | 199,490 | +59.6% | 0.14% | -61.4% | |
| CRIS | Sell | CURIS INC | $833,000 | -73.1% | 350,000 | -46.2% | 0.13% | -88.2% |
| New | CELULARITY INCput | $697,000 | – | 80,000 | +100.0% | 0.11% | – | |
| CNTA | Sell | CENTESSA PHARMACEUTICALS PLCsponsored ads | $586,000 | -87.6% | 65,282 | -84.4% | 0.09% | -94.5% |
| CALA | New | CALITHERA BIOSCIENCES INC | $404,000 | – | 1,000,000 | +100.0% | 0.06% | – |
| IMTXW | Sell | IMMATICS N.V*w exp 07/01/202 | $328,000 | -60.7% | 187,204 | -1.5% | 0.05% | -82.8% |
| HYPERFINE INC | $270,000 | -51.1% | 76,162 | 0.0% | 0.04% | -78.5% | ||
| BPMC | New | BLUEPRINT MEDICINES CORP | $127,000 | – | 1,988 | +100.0% | 0.02% | – |
| RENOVACOR INC*w exp 99/99/999 | $26,000 | -39.5% | 75,000 | 0.0% | 0.00% | -75.0% | ||
| MSACW | MEDICUS SCIENCES ACQUISITION*w exp 02/12/202 | $14,000 | -41.7% | 33,333 | 0.0% | 0.00% | -77.8% | |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -20,000 | -100.0% | -0.14% | – |
| ALDX | Exit | ALDEYRA THERAPEUTICS INC | $0 | – | -100,759 | -100.0% | -0.15% | – |
| RFL | Exit | RAFAEL HLDGS INCput | $0 | – | -101,200 | -100.0% | -0.19% | – |
| INO | Exit | INOVIO PHARMACEUTICALS INCcall | $0 | – | -200,000 | -100.0% | -0.36% | – |
| SEER | Exit | SEER INCcall | $0 | – | -50,000 | -100.0% | -0.41% | – |
| NTLA | Exit | INTELLIA THERAPEUTICS INC | $0 | – | -10,000 | -100.0% | -0.43% | – |
| ARKG | Exit | ARK ETF TRcall | $0 | – | -25,000 | -100.0% | -0.56% | – |
| CVAC | Exit | CUREVAC N Vcall | $0 | – | -50,000 | -100.0% | -0.62% | – |
| Exit | PROCEPT BIOROBOTICS CORP | $0 | – | -100,000 | -100.0% | -0.91% | – | |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -20,000 | -100.0% | -1.06% | – |
| ENVI | Exit | ENVIRONMENTAL IMPACT ACQU CO | $0 | – | -300,000 | -100.0% | -1.08% | – |
| SNDX | Exit | SYNDAX PHARMACEUTICALS INC | $0 | – | -175,000 | -100.0% | -1.39% | – |
| ARYD | Exit | ARYA SCIENCES ACQU CORP IVcl a | $0 | – | -400,000 | -100.0% | -1.44% | – |
| CRIS | Exit | CURIS INCcall | $0 | – | -1,050,000 | -100.0% | -1.82% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -145,552 | -100.0% | -2.41% | – |
| NVAX | Exit | NOVAVAX INCput | $0 | – | -50,000 | -100.0% | -2.60% | – |
| MRNA | Exit | MODERNA INCput | $0 | – | -30,000 | -100.0% | -2.77% | – |
| BBIO | Exit | BRIDGEBIO PHARMA INC | $0 | – | -494,046 | -100.0% | -2.99% | – |
| ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -100,000 | -100.0% | -3.38% | – |
| SAVA | Exit | CASSAVA SCIENCES INCput | $0 | – | -350,000 | -100.0% | -5.55% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MORPHIC HOLDING INC | 12 | Q3 2023 | 6.9% |
| KURA ONCOLOGY INC | 12 | Q3 2023 | 7.2% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 1.9% |
| IMMATICS N.V | 12 | Q3 2023 | 0.4% |
| CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.4% |
| ESTABLISHMENT LABS HLDGS INC | 11 | Q3 2023 | 8.3% |
| VINCERX PHARMA INC | 11 | Q2 2023 | 4.5% |
| ASCENDIS PHARMA A/S | 11 | Q3 2023 | 4.9% |
| CYTOKINETICS INC | 11 | Q3 2023 | 2.6% |
| INARI MED INC | 10 | Q1 2023 | 6.4% |
View Affinity Asset Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 03, 2023 | 7,477,000 | 9.2% |
View Affinity Asset Advisors, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-21 |
| 13F-HR | 2023-08-14 |
| SC 13G | 2023-07-03 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-13 |
View Affinity Asset Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.